TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Mazzola A, Costantino A, Petta S, et al. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol. 2015;11(21):2923–2936. doi:10.2217/fon.15.239
   Web of Science ®Google Scholar
• Kumar AM, Fredman ET, Coppa C, El-Gazzaz G, Aucejo FN, Abdel-Wahab M. Patterns of cancer recurrence in localized resected hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14(3):269–275. doi:10.1016/s1499-3872(15)60382-4
   Web of Science ®Google Scholar
• Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412(2):179–190. doi:10.1042/bj20080281
   PubMed Web of Science ®Google Scholar
• Mehta MS, Vazquez A, Kulkarni DA, et al. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res Treat. 2011;125(3):861–868. doi:10.1007/s10549-010-1062-1
   Web of Science ®Google Scholar
• Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 2008;8:163. doi:10.1186/1471-2407-8-163
   Web of Science ®Google Scholar
• Geng H, Li S, Guo Y, et al. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations. Cancer Biomark. 2020;27(4):525–532. doi:10.3233/cbm-191204
   PubMed Web of Science ®Google Scholar
• Lee YH, Do SK, Lee SY, et al. TSC2 genetic variant and prognosis in non-small cell lung cancer after curative surgery. Thorac Cancer. 2019;10(2):335–340. doi:10.1111/1759-7714.12951
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jia QA, Kadel D, Zhang XF, Zhang QB. Targeting mTORC1/2 complexes inhibit tumorigenesis and enhance sensitivity to 5-fluorouracil (5-FU) in hepatocellular carcinoma: a preclinical study of mTORC1/2-targeted therapy in hepatocellular carcinoma (HCC). Med Sci Monit. 2018;24:2735–2743. doi:10.12659/msm.907514
   PubMed Web of Science ®Google Scholar
• Cho J, Lee J, Kim J, et al. Loss of tuberous sclerosis complex 2 (TSC2) as a predictive biomarker of response to mTOR inhibitor treatment in patients with hepatocellular carcinoma. Transl Oncol. 2016;9(5):466–471. doi:10.1016/j.tranon.2016.08.009
   PubMed Web of Science ®Google Scholar
• Huynh H, Hao HX, Chan SL, et al. Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol Cancer Ther. 2015;14(5):1224–1235. doi:10.1158/1535-7163.mct-14-0768
   Web of Science ®Google Scholar
• European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–1315. doi:10.1016/0092-8674(93)90618-z.
   PubMed Web of Science ®Google Scholar
• Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 2020;12(2):491. doi:10.3390/cancers12020491
   PubMed Web of Science ®Google Scholar
• Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–137. doi:10.1007/s12072-018-9919-1
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_6
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293. doi:10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol. 2014;6(11):776–782. doi:10.4254/wjh.v6.i11.776
   Google Scholar
• Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and −2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–13576. doi:10.1073/pnas.202476899
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–511. doi:10.1038/ng.3252
   PubMed Web of Science ®Google Scholar
• Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46(12):1267–1273. doi:10.1038/ng.3126
   PubMed Web of Science ®Google Scholar
• Ho DWH, Chan LK, Chiu YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2017;66(8):1496–1506. doi:10.1136/gutjnl-2016-312734
   PubMed Web of Science ®Google Scholar
• Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–738. doi:10.1016/j.jhep.2017.05.014
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lv P, Wang S, Cai Q, Zhang B, Huo F. LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis. Gene. 2019;712:143944. doi:10.1016/j.gene.2019.143944
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102. doi:10.1038/nrc.2017.109
   PubMed Web of Science ®Google Scholar
• Huang KT, Huang YH, Li P, et al. Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy. Hepatol Res. 2014;44(11):1142–1150. doi:10.1111/hepr.12256
   Web of Science ®Google Scholar
• Peng Q, Lao X, Chen Z, et al. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2013;8(12):e82773. doi:10.1371/journal.pone.0082773
   Web of Science ®Google Scholar